No abstract

No abstract

Conclusion:The high performing team (in number) had highest number of DCLCs (55%). Our readmission rates were comparable to the National Average. National Average targets for DCLC can be achieved at relatively smaller organizations like DG Hospitals provided that Cholecystectomy is considered as a Day Case procedure by default and clear criteria for patient selection are established and implemented. Aims: Accurate and complete documentation on admission to hospital is vital for communicating acute clinical information and is essential medicolegally. Structured documentation has been shown to improve doctor performance and patient outcomes. We aimed to design a surgical clerking form and evaluate its impact on documentation during this critical period.

IntroductionFrom 2005 to 2011 two large UK studies recruited 6,327 evaluable patients with Barrett’s Oesophagus attending hospital clinics. Baseline clinical, patient history and quality of life data was collected prior to randomisation and this rich dataset is the basis for this abstract.MethodsPatients were recruited to AspECT and BOSS at local centres through normal endoscopy clinics and surveillance lists including those newly diagnosed or with an existing diagnosis of Barrett’s oesophagus.Baseline information was collected on age, gender, ethnicity, length of Barrett’s, presence of hiatus hernia, intestinal metaplasia and low grade dysplasia, concomitant medications, comorbidities, duration and severity of symptoms and patients’ self-reported Quality of Life data.ResultsThe sample was mainly male (75%, n = 6,327) with median age of 64 years (range 18–92 years, n = 6,327). Median Barrett’s length was 4 cm (range 1–24 cm, n = 6,029) and median time since diagnosis of Barrett’s was 2 years (range 0–41 years, n = 5,805). At least one symptom of reflux was experienced by 60% of patients and 46% of patients experienced at least one symptom at least once per week (n = 1,072). Length of Barrett’s was associated with age (n = 6,029), gender (n = 6,029), presence of low grade dysplasia (n = 5,955), presence of intestinal metaplasia (n = 6,026) and time since diagnosis (n = 5,913).ConclusionThis is our first release of data from AspECT and BOSS with more to follow. It is a large set of data on Barrett’s patients which we expect to be typical of Barrett’s patients attending hospital clinics in the UK. The average person was a male age 62 with 4 cm Barrett’s having had a Barrett’s diagnosis for 2 years.AcknowledgementsOur thanks to the patients and the sites.AspECT is sponsored by the University of Oxford with grant funding from CR-UK (A4584) and support from the Investigator-Sponsored Study Program of AstraZeneca with trial management provided by OCTO.BOSS is funded by the HTA grant number HTA 05/12/01 with trial management provided by BOSS trial office Gloucestershire Hospitals NHS Trust.The Centre for Statistics in Medicine provides statistical input to both AspECT and BOSS.Disclosure of InterestNone Declared

patients with Barrett's Oesophagus attending hospital clinics. Baseline clinical, patient history and quality of life data was collected prior to randomisation and this rich dataset is the basis for this abstract. Methods: Patients were recruited to AspECT and BOSS at local centres through normal endoscopy clinics and surveillance lists including those newly diagnosed or with an existing diagnosis of Barrett's oesophagus. Baseline information was collected on age, gender, ethnicity, length of Barrett's, presence of hiatus hernia, intestinal metaplasia and low grade dysplasia, concomitant medications, comorbidities, duration and severity of symptoms and patients' self-reported Quality of Life data. Results: The sample was mainly male (75%, n=6,327) with median age of 64 years (range 18-92 years, n=6,327). Median Barrett's length was 4cm (range 1-24 cm, n=6,029) and median time since diagnosis of Barrett's was 2 years (range 0-41 years, n=5,805). At least one symptom of reflux was experienced by 60% of patients and 46% of patients experienced at least one symptom at least once per week (n=1,072). Length of Barrett's was associated with age (n=6,029), gender (n=6,029), presence of low grade dysplasia (n=5,955), presence of intestinal metaplasia (n=6,026) and time since diagnosis (n=5,913). Conclusion: This is our first release of data from AspECT and BOSS with more to follow. It is a large set of data on Barrett's patients which we expect to be typical of Barrett's patients attending hospital clinics in the UK. The average person was a male age 62 with 4 cm Barrett's having had a Barrett's diagnosis for 2 years. Acknowledgements Our thanks to the patients and the sites.